chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Not feeling good; Did not feel like eating; Inappropriate schedule of vaccine administered; Left Arm hurt; This spontaneous case was reported by a patient and describes the occurrence of IMMUNISATION REACTION (Not feeling good), DECREASED APPETITE (Did not feel like eating), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) and VACCINATION SITE PAIN (Left Arm hurt) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047C21A, 013M20A, 030L20A and 004M21A) for COVID-19 prophylaxis.     Concurrent medical conditions included Immunocompromised, Lupus-like syndrome, Blood pressure high and High cholesterol. Concomitant products included METHOTREXATE, METOPROLOL, SIMVASTATIN and SPIRONOLACTONE for an unknown indication.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 100 microgram. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 100 microgram. On 25-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 100 microgram. On 12-May-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Sep-2021, the patient experienced IMMUNISATION REACTION (Not feeling good), DECREASED APPETITE (Did not feel like eating), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) and VACCINATION SITE PAIN (Left Arm hurt). At the time of the report, IMMUNISATION REACTION (Not feeling good), DECREASED APPETITE (Did not feel like eating), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) and VACCINATION SITE PAIN (Left Arm hurt) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood cholesterol: high cholesterol. On an unknown date, Blood pressure measurement: high blood pressure.     mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No treatment medications were provided by the reporter.  The patient received a 3 dose 100mcg primary series as she was immunocompromised and received a fourth Moderna booster dose. The patient reports no adverse reactions or side effects with the first, second and first-booster doses. Patient was felt like she was coming down with the flu.
fatigue, muscle aches, low grade fever (under 100 degrees) for 6 days now.
Chest pain and Troponin elevation starting 3 days after 2nd dose of COVID vaccine. Suspected mild myocarditis. Normal ejection fraction. Discharged with Ibuprofen for chest pain for suspected pericardial inflammation.
This case was reported by a via call center representative and described the occurrence of petechial rash in a 57-year-old female patient who received SHINGRIX (batch number C523T, expiry date July 2020). The patient's past medical history included depression. Concurrent medical conditions included sulfonamide allergy (had extensive allergy history). Concomitant products included LEVAQUIN. On 9th April 2018, the received the 1st dose of SHINGRIX. In April 2018, less than a week after receiving SHINGRIX, the patient experienced petechial rash. On an unknown date, the outcome of the petechial rash was unknown. It was unknown if the reporter considered the petechial rash to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in her left arm. The pharmacist reported that the patient informed him today that she was experiencing a petechial rash which extends from the left side of her neck to her chest. The patient was on LEVAQUIN when she received SHINGRIX, and was not sure whether or not this was a reaction to the SHINGRIX or LEVAQUIN. The reporter stated that he recommended that the patient take BENADRYL, and was not aware of any medical intervention taken because of patients reaction. The reporter stated that patient had a history of depression and an extensive allergy history. At time of call however he was only able to report that she had a sulfa allergy and stated that he might have to call patient for more information. This case has been linked with case US2018063430 reported by same reporter.
After vaccinated left arm swelling to elbow. Pain radiates to left wrist. Sore throat.
Developed skin reaction in the shape of a large wheel, erythema and swelling lasted 10 days.
loss of hearing in left ear, approx 30-40 reduction, buzzing, pressure in ear
My friend was fully vaccinated got covid on ventilator 14 days then died - how can you say it is safe and effective if you can still get it and die?  Stop this madness of this vaccine NOW!
mom called 1-1 1/2hr p/vax & mom states pt has been constantly screaming & has rash over entire body;
Maternal exposure during breast feeding; This case was received via VAERS (Reference number: 1230062) on 25-May-2021 and was forwarded to Moderna on 25-May-2021.    This regulatory authority case was reported by an other health care professional and describes the occurrence of MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination.     The patient's past medical history included Postural orthostatic tachycardia syndrome. Concurrent medical conditions included Drug allergy (Codeine), Marfan's syndrome and Allergy (Adhesives). Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Mar-2021, the patient experienced MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) (seriousness criterion disability). On 21-Mar-2021, MATERNAL EXPOSURE DURING BREAST FEEDING (Maternal exposure during breast feeding) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This is a case of product exposure during breastfeeding with an associated adverse event of Alopecia areata in the nursing baby. The event started 8 days after the mother's vaccination and was reported as not resolved. No other causes have been identified. Based on temporal association a causal relationship cannot be excluded.; Sender's Comments: This is a case of product exposure during breastfeeding with an associated adverse event of Alopecia areata in the nursing baby. The event started 8 days after the mother's vaccination and was reported as not resolved. No other causes have been identified. Based on temporal association a causal relationship cannot be excluded
My right side of my neck was swollen, making it difficult to chew This was delayed, at day 12 post 2nd vaccine. The same thing happened after the 19 days post 1st vaccine
Pt developed a temperature of 102F, 25-30 fine, red papules on torso, back, neck, extremities and some with small vesicles and pustules on red bases. Also had flat vesicle on sole of feet.
Initial unsolicited report received from a pharmacist on 05 September 2015. This case involves a 67-year-old female patient who was vaccinated with first dose of FLUZONE HD (batch number: UI428AB, expiry date: 19 March 2016) via intramuscular route in right deltoid on 03 September 2015. Reporter denied any illness at time of vaccination, pre-existing physician-diagnosed allergies, birth defects, medical conditions. Concomitant medications were not reported. On 05 September 2015, two days post vaccination, the patient developed redness at injection site, lump at site, warmth and red ring around injection site. Laboratory data and corrective treatments were not reported. At the time of this report, the outcome of the events was unknown. List of documents held by sender: none.
pt had complaint of gripping feeling in side of throat. Benedryl 50mg given, Vital signs all within normal limits. No respiratory distress noted. Patient began to feel better less than 5 minutes after Benedryl given. Pt stayed in clinic for one hour, patient left with symptom resolved.
Client came for second vaccine clinic, had forgotten her card and was given Pfizer instead of Moderna.  The client only recently noticed the difference when she found her first card. She denies and sickness or complications after the Pfizer vaccine was given.
Initial report received from a health care professional on 15 February 2011. A 53-year-old male patient with a history of melanoma received on 09 February 2011 at 09:05 AM an intramuscular left deltoid injection of MENACTRA, lot number U2754AA. The patient's concomitant medication was ezetimibe and VYTORIN 1/2 pill daily (OD). The patient had no other vaccinations within 4 weeks of the MENACTRA. On 10 February 2011, the patient developed a headache which lasted for 12 hours, fever which lasted for 3 days, racing heart rate which lasted for 6-8 hours and muscle aches which lasted for 3 days. On 11 February 2011, the patient developed nausea which lasted for one day and hives which lasted for 2 days. The patient was treated with ibuprofen and a 24 hour pain reliever. The patient received no prescriptions. The outcome was reported as recovered. Documents held by sender: None.
I got the Moderna booster on September 13, 2021.  On September 14, my blood pressure shot up to 178/92.  I went to the emergency room and was given 2 clonidine.   From that date onward, my blood pressure has been very difficult to control.  I am taking large amounts of blood pressure medications, and more than one.
About thirty-six hours after getting the vaccine the lymph nodes in my neck, under my arm pits, collar bone were swollen for five or six days. I called my doctor and she told me not to worry they had been seeing that. When I went for my mammogram I felt a lump in my left breast and I am now awaiting a diagnostic test.
Patient had a reaction on 3/3/21, one day after 3/2/21 Nivolumab (immunotherapy tenth cycle) dose for her melanoma treatment and second Moderna vaccine was given on 2/28/21. She'd had her first Moderna vaccination with the same timing- three days prior- to her 9th Nivolumab infusion. She did not have any prior symptoms after the Moderna vaccines were given.  On 3/3/21 the arm where the vaccine was given became swollen, red, and hot.  She developed a severe sinus headache and sinus congestion with no fluid draining.  The headache pain was more severe than she'd ever experienced and was not like a migraine. "It hurt to blink." She was sick through 3/7 with symptoms progressing to fatigue "too tired to write a note" and nausea and "violent" dry heaves.  The symptoms resolved quickly and completely on Sunday 3/7/21 and she felt well for the days after.
Spiked a fever and the right side of my face and jaw swelled severely. My jaw was huge for 10 days and as hard as a rock. I experienced back to back cold type illnesses and reacted to chemicals, a spider bite and felt generally unwell from the time period preceding the vaccine ( after the ice storm) until June 8th, 2021 when I was attacked and I became acutely I?ll after that and have never recovered. Many doctors have told me the vaccine caused apoptosis and are blaming the vaccine for my condition, however they?re not sharing a lot of test results with me.  My MRI and CT imaging findings are being withheld from me at this time and I?m being told I need an MRI of the brain.  I?d like to know if I have a systemic fungal infection that is affecting my brain and lungs.
Discomfort in stomach, gas then diarrhea through the night...diarrhea next day in afternoon...the next day morning and afternoon.
Patient given expired vaccine; First dose on 31-Aug-21 and second dose on 25-Mar-22; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose on 31-Aug-21 and second dose on 25-Mar-22) in a 79-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 030H21B) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Aug-2021, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 25-Mar-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to .5 milliliter. On 25-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose on 31-Aug-21 and second dose on 25-Mar-22). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose on 31-Aug-21 and second dose on 25-Mar-22) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided by the reporter.  Patient did not have immediate allergic reaction to any vaccine, injection or shot or to any component of COVID-19 vaccine or a severe allergic reaction to anything. Patient did not had history of cancer, leukemia, HIV/AIDS or any other condition that weakens the immune system. In the last 10 days, patient did not have COVID-19 test because of symptoms or isolated or quarantine at home due to COVID-10 infection or exposure. She was not treated with antibody therapy or convalescent plasma for COVID-19 in the past 90 days. Patient was not taking any medications that affect immune system such as cortisone, prednisone or other steroids, anticancer drugs or had radiation treatments. Patient did not have bleeding disorder, a history of blood clots or taking any blood thinner. Patient did not have history of myocarditis or pericarditis.Patient was not feeling sick on the day of vaccination.  No treatment information was provided by the reporter.   This case was linked to MOD-2022-530285 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 31-Mar-2022: Report type changed from invalid to spontaneous. Added patient demographics, vaccine details and new event .
My father received a FLUCELVAX QUADRIVALENT 2017-18 inj. 0.5 no on 2/2/18 and 2 days later had worsening signs of dementia, and began having delusions and paranoia. He already had dementia before the injection but has never had the other problems. His doctors have now added 2 more medications and are running more test. I've spoken with others who's loved ones have had similar reactions. I want to know why people aren't being warned of this! He would not have received it knowing these side effects!
developed Erythem Multiform after receiving / hep-b vaccine and a polio vaccination; This case was reported by a other health professional via call center representative and described the occurrence of erythema multiform-like eruption in a female patient who received Hepatitis B vaccine for prophylaxis.   Co-suspect products included POLIOMYELITIS VACCINE (POLIO VACCINE) for prophylaxis.   Concurrent medical conditions included multiple myeloma.   On an unknown date, the patient received the 1st dose of Hepatitis B vaccine and the 1st dose of POLIO VACCINE. On an unknown date, unknown after receiving Hepatitis B vaccine, the patient experienced erythema multiform-like eruption (serious criteria GSK medically significant). On an unknown date, the outcome of the erythema multiform-like eruption was unknown.   It was unknown if the reporter considered the erythema multiform-like eruption to be related to Hepatitis B vaccine.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Hepatitis B vaccine and Polio vaccine, the patient experienced erythema multiform-like eruption. The patient had tested due to her medical history of Multiple myeloma not related to a vaccine. The reporter consented to follow up. This case was linked with case US2020173731, reported for the same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020173731:same patient
Information has been received from a pediatrician concerning a 17 year old female who on 22-MAR-2007 was vaccinated with a first dose of Gardasil co administered with therapy included MENACTRA on a different arm. On 27-MAR-2007 the patient complained of pain in the thigh and a "creepy, crawly, tingling feeling". She went to the local emergency room (ER). She was admitted to the hospital on 29-MAR-2007. According to the pediatrician all diagnostics came back clear (not further specified). She underwent an ultrasound (results not reported). The patient was seen by a neurologist who hinted a touch of Guillain-Barre. All conditions resolved by early May. The patient did not continue with the series of Gardasil. The pediatrician considered Guillain-Barre to be disabling. Additional information has been requested. 7/3/08-records received- DC summary is not included in a short stay DOS 3/29-3/30/07.Principal diagnosis of this admission: Guillain-Barre syndrome. Presented with C/O dysesthesias and weakness. One 3/19/07 onset of sore throat,  Received vaccinations on that date. Continued to C/O upper respiratory infection symptoms with sinus type headace. Developed discomfort in legs and burning, aching sensation. Tired and generally weak.  PE:diffuse motor weakenss in arms and legs. Deep tendon reflexes brisk. Suggests peripheral neuropathy.  10/10/08-reviewed by CDC CISA staff who determined that this is NOT GBS
Achy, pain in neck & back, diarrhea, weakness, sleepiness. 3 full days. Advil taken for pain.
I got shingles; This is a spontaneous report from a non- contactable consumer, the patient. A 29-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration on 26May2021(at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Jul2021 the patient got shingles. The event resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of shingles and included treatment with unspecified medications. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event  shingles was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected
Within 10 minutes, dizziness, low blood pressure, tingling in both arms Within 24 hours, tingling intensified in left arm, numbness from elbow to finger tips Within 72 hours, tingling in right arm and tongue Issue not resolved, follow up planned with primary and neurology care
Two episodes of malaise, headache, nausea, fever, joint pain starting about 8 hours after vaccine administration.  Second vaccine was given with Benadryl pre-treatment and Tylenol afterward.
Injection site: itching, swelling, soreness, warmth, 3 x2 inches
Unknown vaccine manufacturer, vaccine received at PCP office.  Redness to the area of injection on the right thigh that had spread to down to the knee. The skin was warm to touch. Patient started on keflex for a cellulitis.
Fever, dry cough, no energy, running nose, mucus, scratchy throat all week long and continuing today, Sat. 10/09/2020
Breakthrough case admission after 2 vaccines Moderna 6/13/21 lot# 049C21A;  Moderna 7/1/21 lot# 054C21A
Within one hour post vaccination with AVA #1, and his third typhoid on 23 Feb 11, he began to experience fatigue, and chills. Later that evening he developed a fever with worsening of fatigue and chills, followed by headache and myalgias. The fever lasted 3-4 days with myalgias subsiding during the second week.
pt recv vax 13AUG97 & prior to vax pt had recv 8 doses of prelone to treat bronchitis;@ the time of vax pt was fussy & irritable but afeb;the next day pt devel a rectal temp of 103;
a dose of PEDVAXHIB had been administered after undergoing a temperature excursion; This spontaneous report has been received from a nurse, referring to a male patient of unknown age. The patient's current condition, historical condition and concomitant medication were not provided.  On 11-NOV-2020 the patient was vaccinated with an improperly stored dose of  haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (lot # T000885 with expiration date: 29-MAY-2022; 0.5 ml one time, strength and route were unknown) for prophylaxis (product storage error).   The vaccine was stored above 47 Fahrenheit (F) (50.0F) for 1 hour 21 minutes and 0 seconds. The vaccine was stored below 36F (33.8F) for 0 hours 23 minutes and 0 seconds. The previous temperature excursion included hours: 0; minutes: 21; seconds: 0; temp: 47.8F; hours: 0; minutes: 26; seconds: 0; temp: 49.5F; hours: 0; minutes: 9; seconds: 0; temp: 35F; hours: 0; minutes: 6; seconds: 0; temp: 35.2F; hours: 0; minutes: 8; seconds: 0; temp: 35F; hours: 0; minutes: 10; seconds: 0; temp: 35.2F. The digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2011USA008842:
pt recv vax SEP97 & pt devel a lump @ the inj site;it was reported that MD changed the needle;MD was unsure whether or not to administer subsequent doses;
PFIZER COVID VACCINE #3 GIVEN 9/28/21, LOT #FE3592; pt had a positive COVID test on 1/23/22 at Medical Center; pt admitted to hospital with AMS; dx with stroke and COVID positive; comfort care; family desired inpatient hospice; transferred to Hospice; pt unresponsive and passed away in the facility
Patient felt light-headed and nauseous about 15min after receiving his first dose Pfizer vaccine. I had him lay down with legs elevated for 15 minutes. Took his BP while he was laying down, 139/79. Offered patient a bottle of juice. Patient was feeling back to normal after 15minutes. Seated BP at that time was 140/75. Patient lives with family, will let them know to keep an eye on him. He will pursue medical attention if symptoms return or if new symptoms occur.
Breakthrough case admission after 2 vaccines  Moderna 4/30/21 Lot# 003C21A;  Moderna 5/28/21 Lot# 049C21A
gen rash all over vax given 9AM-rash noticed @ 430Pm;
This case was reported by a healthcare professional and described the occurrence of not responding to therapy in an adult subject of unspecified gender who was vaccinated with ENGERIX B (GlaxoSmithKline). On an unspecified date the subject received 3rd, 2nd dose and 1st dose of ENGERIX B (unknown). At an unspecified time after vaccination series completion with ENGERIX B, the subject experienced not responding to therapy and pharmaceutical product complaint. A total of six employees were vaccinated with three doses of ENGERIX B. All had titers drawn at an unknown period after the third dose and the titers were negative (0) for antibodies. There were two lots given to these six subjects at some point in the series, lots: AHBV13734AA and AHBV670AA. The lot numbers were reported as AHBV13734AA and AHBV670AA from the reporter; however, based on a safety lot review, the lot numbers were updated to AHBVB734AA and AHBVB670AA respectively. For the other cases see A0891212A, A0891213A, A0891215A- A0891217A. Follow-up information was received on 09 November 2010 via Quality Assurance, who stated there was no product complaint associate with the adverse event; therefore the pharmaceutical product complaint was voided.